RxDoctor Payments Data

Christopher Kafka, DO

Family Medicine · Kansas City, MONPI 1629016704

Payments from drug & device makers

$5,356in general payments, 2019–2025

Across 339 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$749
  • AbbVie$620
  • Lilly USA, LLC$555
  • Pfizer$539
  • Novo Nordisk$415
  • Boehringer Ingelheim$292
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,356 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$195,188
Medicare patients
378
Services billed
9,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$183,687
MounjaroTirzepatide148$177,282
EliquisApixaban78$75,375
OzempicSemaglutide48$61,954
JanuviaSitagliptin Phosphate37$34,437
XareltoRivaroxaban20$31,023
TrulicityDulaglutide15$29,603
LinzessLinaclotide29$23,849
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,750
Humalog Kwikpen U-100Insulin Lispro26$17,517
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$16,839
FarxigaDapagliflozin Propanediol16$16,684
Tresiba Flextouch U-100Insulin Degludec18$13,598
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$12,658
Spiriva RespimatTiotropium Bromide11$11,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$555$206,885163 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$292$200,261147 claims
PfizerEliquis, Abrysvo$539$84,209111 claims
Novo NordiskOzempic$415$61,95448 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Arnuity Ellipta$112$47,65386 claims
MerckJanuvia$55$34,43737 claims
Johnson & JohnsonXarelto$63$31,02320 claims
AbbVieLinzess$620$23,84929 claims
AstraZenecaFarxiga, Symbicort$749$23,00132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →